Replies to post #90322 on Biotech Values

[p3analyze]

Does the benefit of delaying Time to Skeletal Events outweighs Increased Risk of ONJ?

One would think the answer is yes, since ONJ has not stopped physician from using Zometa to treat bone mets. Time will tell.

[DewDiligence]

That's a trifecta for denosumab in metastatic cancer (eom).